Trending: Johnson & Johnson to Buy Abiomed
02 November 2022 - 5:19AM
Dow Jones News
13:49 ET -- Johnson & Johnson is one of the most talked
about companies in the U.S. across all news items in the last 12
hours, according to Factiva data. The company agreed to buy
heart-pump maker Abiomed Inc. in an all-cash deal valued at $16.6
billion upfront, including cash. J&J agreed to pay $380 a share
upfront, and would pay an additional $35 a share if certain
milestones are met. Abiomed shares were recently up 50% to $378.85.
J&J shares declined less than 1% to $172.99. Dow Jones &
Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
November 01, 2022 14:04 ET (18:04 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024